NGFN-PLUS
Prostate cancer
Coordinator: | Prof. Dr. Holger Sültmann | |
Institution: | Deutsches Krebsforschungszentrum (DKFZ) | |
Homepage: | http://www.dkfz.de |
The aim of the Integrated Genome Research Project (IG) Prostate Cancer was to utilize the high-throughput technologies that were established within the NGFN towards an improved clinical management of prostate cancer. In order to create the critical mass and synergies required to achieve substantial improvements in this field, we joined the forces of internationally renowned partners in molecular genome analysis, urology, and pathology.
The IG Prostate Cancer covered the entire workflow from the identification of novel molecular marker signatures to data validation in large-scale retrospective analyses as well as a prospective clinical study. The aim was to generate novel validated molecular markers for improving the detection of tumors and for assessing the risk of cancer progression. We performed in-depth functional analysis of biomarkers from cell lines up to the level of mammalian model organisms. With the comprehensive understanding of gene functions enabled by experimental data and bioinformatic network generation and data modeling, the results were expected to deliver novel diagnostic and therapeutic strategies for patient treatment.
The screening experiments in 130 tumor- and normal tissue samples were successfully finished in all subprojects. We identified a large number of novel tumor-relevant genetic alterations, including chromosomal deletions (TP2), aberrant DNA methylation (TP4), differentially expressed genes and miRNAs (TP5) and deregulated proteins and signal transduction pathways (TP6,9). Validation experiments and functional studies gave clues as to the biological consequences of these changes in vitro. Integrative analyses of different molecular data sets (TP13) were performed in order to investigate the added value of data integration for the understanding of the processes driving prostate cancer.
Latest results can be found in detail in the descriptions of the subprojects
The IG Prostate Cancer covered the entire workflow from the identification of novel molecular marker signatures to data validation in large-scale retrospective analyses as well as a prospective clinical study. The aim was to generate novel validated molecular markers for improving the detection of tumors and for assessing the risk of cancer progression. We performed in-depth functional analysis of biomarkers from cell lines up to the level of mammalian model organisms. With the comprehensive understanding of gene functions enabled by experimental data and bioinformatic network generation and data modeling, the results were expected to deliver novel diagnostic and therapeutic strategies for patient treatment.
The screening experiments in 130 tumor- and normal tissue samples were successfully finished in all subprojects. We identified a large number of novel tumor-relevant genetic alterations, including chromosomal deletions (TP2), aberrant DNA methylation (TP4), differentially expressed genes and miRNAs (TP5) and deregulated proteins and signal transduction pathways (TP6,9). Validation experiments and functional studies gave clues as to the biological consequences of these changes in vitro. Integrative analyses of different molecular data sets (TP13) were performed in order to investigate the added value of data integration for the understanding of the processes driving prostate cancer.
Latest results can be found in detail in the descriptions of the subprojects
- TP1 Collectivization and povision of optimized bioresources and clinical data
- TP2 Biological and clinical significance of micro-amplifications in prostate cancer
- TP3 Cytogenetic and molecular genetic characterization of translocation breakpoints
- TP4 Analysis of genetic and epigenetic alterations in prostate cancer
- TP5 Identification of splice variants and miRNAs and their validation as markers and signatures
- TP6 Identification of clinical relevant protein markers of prostate carcinoma
- TP7 Development and commercialising of a diagnostic tool for early diagnosis of prostate cancer
- TP8 Identification and validation of diagnostic and prognostic markers of prostate cancer
- TP9 Quantitaive analysis of signalling pathways using protein microarrays
- TP10 Molecular tumor imaging using antibody-coated nanoparticles
- TP11 Functional assays in prostate carcinoma cell lines
- TP12 In vivo analysis of genes associated with prostate carcinoma in mouse models
- TP13 Bioinformatics and systembiology
- TP14 Coordination, communication and quality management
- Publications
KTT
MEDIA
CURRENT
NGFN-MEETING-2012
NGFN- MEETING
NGFN1&2
LINKS